U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H26N2O2
Molecular Weight 362.4656
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SOLIFENACIN

SMILES

c1ccc(cc1)[C@@]2([H])c3ccccc3CCN2C(=O)O[C@@]4([H])CN5CCC4CC5

InChI

InChIKey=FBOUYBDGKBSUES-VXKWHMMOSA-N
InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H26N2O2
Molecular Weight 362.4656
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.wikidoc.org/index.php/Solifenacin

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in rat. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10 nM [Ki]
125 nM [Ki]
25 nM [Ki]
7.73000000000000043 null [pKi]
7.45999999999999996 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VESICARE

Approved Use

VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency (1)

Launch Date

1100822400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
14.1 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
820 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
50.8 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
SOLIFENACIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg single, oral
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources:
healthy, 19-40
Health Status: healthy
Age Group: 19-40
Sex: M
Sources:
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
healthy, 20-35
Health Status: healthy
Age Group: 20-35
Sex: M
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Dry mouth...
AEs leading to
discontinuation/dose reduction:
Dry mouth (1.5%)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Angioedema, Anaphylactic reaction...
AEs leading to
discontinuation/dose reduction:
Angioedema
Anaphylactic reaction (rare)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dry mouth 1.5%
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Angioedema Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Anaphylactic reaction rare
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victimTox targets

Tox targets

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.
2004
Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.
2004 Jan
In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
2004 May 25
Pharmacokinetics and safety of solifenacin succinate in healthy young men.
2004 Sep
[Neurological aspect of the hyperactive urinary bladder syndrome].
2005
Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.
2005 Jan
Role of muscarinic receptor antagonists in urgency and nocturia.
2005 Sep
Gateways to clinical trials.
2006 Apr
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
2006 Aug
Muscarinic receptors in the bladder: from basic research to therapeutics.
2006 Feb
New drugs 06, part I.
2006 Feb
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
2006 Jul
Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence.
2006 Jun
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
2006 Mar
Pharmacologic management of overactive bladder: practical options for the primary care physician.
2006 Mar
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis.
2006 Sep
Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency.
2007 Jan
Patents

Sample Use Guides

5 mg tablet taken once daily, and if well tolerated may be increased to 10 mg once daily.
Route of Administration: Oral
The inhibitory effect of solifenacin (dose range: 10^-10 - 10^-6 M) for bladder smooth muscle cells (pK(i)=8.12) was 3.6-fold more potent than that for salivary gland cells (pK(i)=7.57).
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:09:49 UTC 2021
Edited
by admin
on Fri Jun 25 22:09:49 UTC 2021
Record UNII
A8910SQJ1U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SOLIFENACIN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
SOLIFENACIN [INN]
Common Name English
NSC-759144
Code English
SOLIFENACIN [MI]
Common Name English
SOLIFENACIN [WHO-DD]
Common Name English
SOLIFENACIN [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC G04CA53
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
NDF-RT N0000000125
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
WHO-ATC G04BD08
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
NDF-RT N0000000125
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
WHO-VATC QG04CA53
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
LIVERTOX 892
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
NDF-RT N0000000125
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
WHO-VATC QG04BD08
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
NCI_THESAURUS C29704
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
NDF-RT N0000175700
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
Code System Code Type Description
RXCUI
322167
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
MESH
C441209
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
LACTMED
Solifenacin
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
MERCK INDEX
M10108
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY Merck Index
INN
8155
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
DRUG CENTRAL
2457
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
DRUG BANK
DB01591
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
EVMPD
SUB21589
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
EPA CompTox
242478-37-1
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
CAS
242478-37-1
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
IUPHAR
7483
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
ChEMBL
CHEMBL1734
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
NCI_THESAURUS
C75284
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
FDA UNII
A8910SQJ1U
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
PUBCHEM
154059
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
WIKIPEDIA
SOLIFENACIN
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
PRIMARY
RXCUI
477364
Created by admin on Fri Jun 25 22:09:49 UTC 2021 , Edited by admin on Fri Jun 25 22:09:49 UTC 2021
ALTERNATIVE
Related Record Type Details
TARGET -> INHIBITOR
Appears to be more bladder-selective for the M3 receptor relative to salivary glands.eptor
Ki
METABOLIC ENZYME -> SUBSTRATE
MINOR
TARGET->WEAK INHIBITOR
Ki
BINDER->LIGAND
in vivo
BINDING
EXCRETED UNCHANGED
URINE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Ki
Related Record Type Details
METABOLITE INACTIVE -> PARENT
major in urine
MAJOR
PLASMA; URINE
METABOLITE ACTIVE -> PARENT
major in urine
MAJOR
PLASMA; URINE
METABOLITE INACTIVE -> PARENT
MINOR
PLASMA
METABOLITE ACTIVE -> PARENT
occurs at low concentrations and unlikely to contribute significantly to clinical activity
MINOR
PLASMA
METABOLITE ACTIVE -> PARENT
MAJOR
URINE
METABOLITE ACTIVE -> PARENT
FECAL
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

AT STEADY-STATE

Biological Half-life PHARMACOKINETIC